Historically in healthcare, technology developments have outpaced clinical researchers’ ability to leverage these advancements. However, that trend seems to be changing – particularly as it pertains to digital technology and devices. The penetration of mobile devices worldwide is over 50% with close to 4 billion users – and they are quickly becoming our primary tool to monitor health behaviors and collect relevant data. Mobile adoption could help to accelerate clinical research like never before.
Read the rest of this entry »
Posted in Our Views | No Comments »
Agilent is investing $80 million in our client Lasergen, an emerging biotechnology company with innovative next-generation sequencing (NGS) technology. The two companies will collaborate on building a NGS solutions workflow for clinical applications, based on Lasergen’s Lightning Terminators™ sequencing chemistry.
This recent investment showcases the trend toward new players and innovative technology in the NGS space, particularly as the technology moves to more routine clinical use.
Lasergen’s relationship with Agilent is another example of how Popper and Company helps companies create transformative business partnerships.
Tags: biotech, diagnostics, digital health, sequencing
Posted in Diagnostics, Our Views | No Comments »